Cefotaxime

C. diff Risk

High

Oral Bioavailability

NA

Approximate Cost

Reserved for Pediatrics

Dosing

1-2g IV q4-12h

1-2 g q24h (or reduce usual dosing by 50%)
CrCl Less Than 10 mL/min

1-2g q6-12h
CrCl 10-24 mL/min

1-2g q6-12h
CrCl 25-49 mL/min

1-2 g q4-12h
CrCl Greater Than 50 mL/min

General Information

Common Usage

Empiric therapy for:

  •  Bacterial meningitis

  •  Pneumonia (in combination with a macrolide)

  •  Intra-abdominal infection including SBP

  •  Musculoskeletal i.e. septic arthritis

  •  Urinary tract infection

Adverse Effects

  •  Rash

  •  Localized phlebitis at injection site

  •  Allergy

  •  Positive Coombs test

  •  Neutropenia

  •  Abnormalities in liver enzymes

  •  Diarrhea

  •  CDI

Additional Information

Reserved for use in Paediatrics.

Pharmacology

Antimicrobial class: 3rd Generation Cephalosporin

Pregnancy category: B

Average serum half life: 1.5 hours

Urine penetration: Therapeutic

Lung penetration: Therapeutic

Biliary penetration: Moderate

CSF penetration: Therapeutic when inflamed meninges